Showing posts with label VVUS. Show all posts
Showing posts with label VVUS. Show all posts

Monday, July 11, 2011

ICResearch Q2 2011 Performance (BKS, PHH, QCOR, VVUS, RCL, LL, ODP, EK, BBY, WFC, CREE, AIG, LOGI, PHG, WWE, NYB, LCC, CCL)

InvestingConsultantResearch.com today announced results for the quarterly performance of it's recommendations made for the second quarter of 2011. Here is how those recommendations for Q2 2011 performed since they were issued, ordered by return for the cautious investor if they had been held until market closes at the end of the second quarter of 2011 or when the bid price reached the level provided in the exit strategy.

To be fairly representative of the potential performance, the return presents what an investor would have earned opening the position at the prevailing price when the report was issued and closing it when the bid price of the stock reached the suggested exit point. If the stock did not reach any of the exit levels, the closing price at the end of the quarter is considered to be the selling price.


For the cautious investor:
BKS+ 120%
QCOR+ 85%
VVUS+ 43%
WDC: + 40%
DYAX: + 32%
CRU: + 32%
ARNA: + 30%
IGOI: + 30%
RCL: + 29%
DV: + 29%
EXF: + 27%
EXFO: + 25%
FCN+ 22%
SYNA+ 21%
AXL+ 18%
FBC+ 18%
VCI+ 18%
SANM+ 18%
MDAS+ 17%
LCC+ 17%
SWM+ 15%
FLML+ 15%
RDN+ 13%
LL+ 13%
ORN+ 12%
ODP+ 12%
EK+ 11%
MTOR+ 11%
BORN+ 10%
BBY+ 10%
JACK+ 10%
ENG+ 7%
LOJN+ 7%
PHH+ 7%
FEED+ 5%
XRTX+ 5%
SCCO+ 5%
RJET+ 4%
BPL+ 4%
WFSL+ 4%
NYB+ 4%
WFC+ 2%
FRO+ 1%
HBOS: - 1%
CREE- 2%
PHG- 2%
CCL- 2%
LOGI- 4%
LPS- 6%
RECN- 8%
AIG- 9%
WWE- 11%
SATC- 14%
ANAD- 20%
HSOL- 25%
MTSN- 26%

Average Return: + 13%


Once again, the return presents what an investor would have earned opening the position at the prevailing price of the option contract when the report was issued and closing it when the bid price of the contract reached the suggested exit point. If the stock did not reach any of the exit levels, the closing bid price at the end of the quarter is considered to be the selling price of the option contract.


For the risk taking trader:

Average Return: + 66%


Most of InvestingConsultantResearch.com's picks returned modest performance and some even suffered losses, but the losses were offset by the provided exit strategy. Subscribe to our our site to stay informed for forthcoming recommendations for Q3 and Q4 2011 or follow us on Twitter.

Monday, March 7, 2011

VIVUS Inc (NASDAQ: VVUS) Q2 2011 Price Target

Recent price: 6.35$
P/E Ratio: -
3 Months Target Price: 9.00$

Company Description
VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health. The company's lead investigational product in clinical development, Qnexa®, has completed phase 3 clinical trials for the treatment of obesity and an NDA has been filed and accepted by the FDA, with an action date of October 28, 2010. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction. MUSE® (alprostadil), a first generation therapy for the treatment of ED, is already commercially available and generating revenue for VIVUS.


Confidence Margins
Strong resistance $11.48 (+81%)
Light resistance $9.05 (+43%)
Light support $6.08 (-4%)
Strong support $5.28 (-17%)

Recommendation
Coming from a press release dating back in February 21st 2011, this stock fell recently because of an end-of-review FDA meeting where the FDA asked the company for more birth defects data for its experimental obesity drug Qnexa. This will force VIVUS to resubmit for the approval their new investigational drug, QXENA NDA, for the treatment of obesity. This provides a great entry point for the coming quarter.

Entry strategy
For the cautious investor:
Buy the stock for 7.00$ or less.

For the risk-taking trader:
The June 2011 7$ out-of-the-money call option contract seems to be the right position to take, they can be acquired for about 78$ per contract.

Exit Strategy
For the cautious investor:
Sell when the stock reaches 9$, or keep it until 11$ if you are more bullish in your own analysis. Keep the stock on watch if it crosses the support line.

For the risk-taking trader:
The contracts should be kept until the underlying reaches around 9$. This should provide a satisfactory return if the underlying reaches the target price as the contracts will get in the money.